Skip to main content
. Author manuscript; available in PMC: 2018 Dec 13.
Published in final edited form as: J Natl Compr Canc Netw. 2018 Oct;16(10):1166–1170. doi: 10.6004/jnccn.2018.7056

Figure 2.

Figure 2.

Marked response to dabrafenib and trametinib demonstrated by restaging imaging. PET/CT scans performed before and after initiation of treatment with dabrafenib and trametinib show a robust response to treatment. Pretreatment and posttreatment scans were performed at 6, 13, 17, and 21 months after initial diagnosis (A–D, respectively). Most strikingly, there is complete resolution of the vertebral lesions. The new right ischial lesion noted in (C) portended the progression of disease through treatment that was demonstrated 3 months later.